• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

CellRight Technologies

7 medtech stories we missed this week: March 16, 2018

March 16, 2018 By Danielle Kirsh

From Intricon expanding its manufacturing space to Arthrex signing a global distribution deal, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Intricon expands medical footprint Intricon announced in a March 13 press release that it has signed a 5-year lease that will secure 30,000 sq. ft of manufacturing […]

Filed Under: 510(k), Contract Manufacturing, Diagnostics, Hospital Care, Imaging, Orthopedics, Patient Monitoring, Regulatory/Compliance, Software / IT, Spine Tagged With: Arch Therapeutics, Arthrex Inc., CellRight Technologies, Enhatch, Guided Therapeutics Inc., IntriCon Corp., Life Spine Inc., unitedhealthproducts

Tissue Regenix closes $30m CellRight acquisition

August 9, 2017 By Fink Densford

Tissue Regenix (LON:TRX) said today it closed its $30 million (£23 million) acquisition of CellRight Technologies and its line of spinal surgery and orthopedic products. Leeds, England-based Tissue Regenix said it expects that the acquisition will increase its US sales by more than double while expanding the company’s presence in the US healthcare market. Tissue Regenix’s technology is […]

Filed Under: Business/Financial News, Mergers & Acquisitions, Regenerative Medicine Tagged With: CellRight Technologies, Tissue Regenix

Tissue Regenix slides after $30m buyout of CellRight Technologies

July 21, 2017 By Brad Perriello

Tissue Regenix (LON:TRX) shares came under pressure today after the regenerative medicine company said it paid $30 million (£23 million) to acquire CellRight Technologies and its line of spine surgery and orthopedics products. Leeds, U.K.-based Tissue Regenix said it funded the deal with a $52 million (£40 million) flotation of 400 million shares. CellRight is based in San Antonio, […]

Filed Under: Funding Roundup, Mergers & Acquisitions, Regenerative Medicine, Wall Street Beat Tagged With: CellRight Technologies, Tissue Regenix

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS